{
  "source": "PA-Med-Nec-Actemra_Tyrenne.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2194-13\nProgram Prior Authorization/Medical Necessity\nMedication *Actemra® (tocilizumab) and Tyenne® (tocilizumab-aazg)\n*This program applies to the subcutaneous formulation of tocilizumab.\nP&T Approval Date 5/2020, 4/202, 6/2021, 12/2021, 4/2022, 11/2022, 1/2023, 4/2023,\n7/2023, 2/2024, 10/2024, 12/2024, 4/2025\nEffective Date 6/1/2025\n1. Background:\nTocilizumab [Actemra (tocilizumab) and Tyenne (tocilizumab-aazg)] is an interleukin-6 (IL-6)\nreceptor antagonist, available in both an intravenous and a subcutaneous formulation.\nSubcutaneous formulations of tocilizumab are indicated for the treatment of adult patients with\nmoderately to severely active rheumatoid arthritis who have had an inadequate response to one\nor more disease-modifying anti-rheumatic drugs (DMARDs). It is also indicated for giant cell\narteritis in adult patients, the treatment of active polyarticular juvenile idiopathic arthritis\n(PJIA) and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and\nolder, and for slowing the rate of decline in pulmonary function in adult patients with systemic\nsclerosis-associated interstitial lung disease (SSc-ILD).\n2. Coverage Criteriaa:\nA. Giant Cell Arteritis (GCA)\n1. Initial Authorization\na. Actemra or Tyenne will be approved based on all of the following criteria:\n(1) Diagnosis of giant cell arteritis\n-AND-\n(2) Patient is not receiving Actemra or Tyenne in combination with another\ntargeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\n-AND-\n(3) Prescribed by or in consultation with a rheumatologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Actemra or Tyenne will be approved based on both of the following criteria:\n© 2025 UnitedHealthcare Services, Inc.\n1\n(1) Documentation of positive clinical response to Actemra or Tyenne ther",
    "zation\na. Actemra or Tyenne will be approved based on both of the following criteria:\n© 2025 UnitedHealthcare Services, Inc.\n1\n(1) Documentation of positive clinical response to Actemra or Tyenne therapy\n-AND-\n(2) Patient is not receiving Actemra or Tyenne in combination with another\ntargeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nB. Rheumatoid Arthritis (RA)\n1. Initial Authorization\na. Actemra or Tyenne will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active rheumatoid arthritis\n-AND-\n(2) One of the following:\n(a) History of failure to a 3 month trial of one non-biologic disease modifying\nanti-rheumatic drug (DMARD) [e.g., methotrexate, leflunomide,\nsulfasalazine, hydroxychloroquine] at maximally indicated doses, unless\ncontraindicated or clinically significant adverse effects are experienced\n(document drug, date, and duration of trial).b^\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of rheumatoid arthritis as documented by claims\nhistory or submission of medical records (Document drug, date, and\nduration of therapy) [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]\n-AND-\n(3) One of the following:\n(a) History of failure, contraindication, or intolerance to two of the following\npreferred products (Document drug, date, and duration of trial):\ni. One of the preferred adalimumab productsc\nii. Cimzia (certolizumab)\niii. Enbrel (etanercept)\niv. Rinvoq (upadacitinib)\nv. Simponi (golimumab)\n© 2025 UnitedHealthcare Services, Inc.\n2\nvi. Xeljanz/Xeljanz XR (tofacitinib)\n-OR-\n(b) Both of the following:\ni. Patient is currently on Actemra or Tyenne therapy as documented by\nclaims histor",
    "mumab)\n© 2025 UnitedHealthcare Services, Inc.\n2\nvi. Xeljanz/Xeljanz XR (tofacitinib)\n-OR-\n(b) Both of the following:\ni. Patient is currently on Actemra or Tyenne therapy as documented by\nclaims history or submission of medical records (Document date and\nduration of therapy)\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from a manufacturer\nsponsored program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Actemra or Tyenne*\n-AND-\n(4) Patient is not receiving Actemra or Tyenne in combination with another\ntargeted immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),\nOlumiant (baricitinib), Rinvoq (upadacitinib)]\n-AND-\n(5) Prescribed by or in consultation with a rheumatologist\n* Patients requesting initial authorization who were established on therapy via the\nreceipt of a manufacturer supplied sample at no cost in the prescriber’s office or any\nform of assistance from a manufacturer sponsored program shall be required to meet\ninitial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Actemra or Tyenne will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Actemra or Tyenne therapy\n-AND-\n(2) Patient is not receiving Actemra or Tyenne in combination with another\ntargeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nXeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n3\nC. Polyarticular Juvenile Idiopathic Arthritis (PJIA)\n1. Initial Authorization\na. Actemra or Tyenne will be approved based on all of the following criter",
    "nths.\n© 2025 UnitedHealthcare Services, Inc.\n3\nC. Polyarticular Juvenile Idiopathic Arthritis (PJIA)\n1. Initial Authorization\na. Actemra or Tyenne will be approved based on all of the following criteria:\n(1) Diagnosis of active polyarticular juvenile idiopathic arthritis\n-AND-\n(2) Patient is not receiving Actemra or Tyenne in combination with another\ntargeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nXeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]\n-AND-\n(3) Prescribed by or in consultation with a rheumatologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Actemra or Tyenne will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Actemra or Tyenne therapy\n-AND-\n(2) Patient is not receiving Actemra or Tyenne in combination with another\ntargeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nXeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nD. Systemic Juvenile Idiopathic Arthritis (SJIA)\n1. Initial Authorization\na. Actemra or Tyenne will be approved based on all of the following criteria:\n(1) Diagnosis of active systemic juvenile idiopathic arthritis\n-AND-\n(2) Patient is not receiving Actemra or Tyenne in combination with another\ntargeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\n© 2025 UnitedHealthcare Services, Inc.\n4\nXeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]\n-AND-\n(3) Prescribed by or in consultation with a rheumatologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Actemra or Tyenne will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Actemra or Tyenne therapy\n-AND-\n(2) Patient",
    "months.\n2. Reauthorization\na. Actemra or Tyenne will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Actemra or Tyenne therapy\n-AND-\n(2) Patient is not receiving Actemra or Tyenne in combination with another\ntargeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nXeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nE. Systemic sclerosis-associated interstitial lung disease\n1. Initial Authorization\na. Actemra or Tyenne will be approved based on all of the following criteria:\n(1) Diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD) as\ndocumented by all of the following criteria:4\n(a) One of the following:\ni. Skin thickening of the fingers of both hands extending proximal to the\nmetacarpophalangeal joints\n-OR-\nii. At least two of the following:\n• Skin thickening of the fingers (e.g., puffy fingers, sclerodactyly of\nthe fingers)\n• Fingertip lesions (e.g., digital tip ulcers, fingertip pitting scars)\n• Telangiectasia\n• Abnormal nailfold capillaries\n• Pulmonary arterial hypertension\n• Raynaud’s phenomenon\n• SSc-related autoantibodies (e.g., anticentromere, anti-topoisomerase\nI, anti-RNA polymerase III)\n© 2025 UnitedHealthcare Services, Inc.\n5\n-AND-\n(b) Presence of interstitial lung disease as determined by finding evidence of\npulmonary fibrosis on HRCT, involving at least 10% of the lungs\n-AND-\n(2) Patient is not receiving Actemra or Tyenne in combination with another\ntargeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nXeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]\n-AND-\n(3) Prescribed by or in consultation with a pulmonologist\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Actemra or Tyenne will be approved based on both of the following cri",
    "]\n-AND-\n(3) Prescribed by or in consultation with a pulmonologist\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Actemra or Tyenne will be approved based on both of the following criterion:\n(1) Documentation of positive clinical response to Actemra or Tyenne therapy.\n-AND-\n(2) Patient is not receiving Actemra or Tyenne in combination with another\ntargeted immunomodulator [e.g., Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nXeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.\nc For a list of preferred products please reference drug coverage tools.\n^ Tried/Failed alternative(s) are supported by FDA labeling\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n© 2025 UnitedHealthcare Services, Inc.\n6\nThe intravenous infusion is typically covered under the medical benefit. Please refer to the United\nHealthcare Drug Policy for Tocilizumab.\n4. References:\n1. Actemra [package insert]. South San Francisco, CA: Genentech, Inc.; June 2022.\n2. Tyenne [package insert]. Lake Zurich, IL: Fresenius Kabi USA, LLC; March 2024\n3. Pavy S. Constantin A, Pham T, et al. Methotrexate therapy for rheumatoid arthritis: clinical\npractice guidelines based on published evidence and expert opinions. Joint Bone Spine\n2006;73(4):388-95.\n4. Singh JA, Saag KG, Bridges SL, et al. 2015 Am",
    "ate therapy for rheumatoid arthritis: clinical\npractice guidelines based on published evidence and expert opinions. Joint Bone Spine\n2006;73(4):388-95.\n4. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for\nthe Treatment of Rheumatoid Arthritis. Arthritis Care & Research. Arthritis Rheum.\n2016;68(1):1-26.\n5. van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification criteria for systemic sclerosis:\nan American College of Rheumatology/European League against Rheumatism collaborative\ninitiative. Ann Rheum Dis 2013;72:1747-1755.\nProgram Prior Authorization/Medical Necessity - Actemra (tocilizumab) and\nTyenne (tocilizumab-aazg)\nChange Control\n5/2020 New program.\n4/2021 Added coverage criteria for systemic sclerosis-associated interstitial\nlung disease. Updated background and references.\n6/2021 Removed prescriber requirement from reauthorization criteria. Added\ncoverage criteria for patients previously treated with a biologic\nDMARD for rheumatoid arthritis. Added clarification that submission\nof medical records is required documenting current therapy with\nActemra in order to bypass step if claim history not available for\nrheumatoid arthritis.\n12/2021 Updated the following with no change to clinical intent: updated\nconventional DMARD bypass language for rheumatoid arthritis,\nremoved “biologic” from required preferred product criteria language\nand updated CT/KY footnote.\n4/2022 Updated background to reflect both formulations being approved for\nGCA. Updated references.\n11/2022 Added Enbrel as a preferred product step option for RA. Added Enbrel\nas an example where appropriate. Added Mississippi to state mandate\nfootnote. Updated reference.\n1/2023 Updated step therapy requirements to Humira or Amjevita. Updated\nlisted examples from Humira to adalimumab.\n4/2023 Updated step therapy requirement from Humira or Amjevita to one of\nthe preferred adalimumab products and added the footnote “For a list of\npreferred adalimumab products plea",
    "mira to adalimumab.\n4/2023 Updated step therapy requirement from Humira or Amjevita to one of\nthe preferred adalimumab products and added the footnote “For a list of\npreferred adalimumab products please reference drug coverage tools.”\nUpdated examples JAK-I with Rinvoq.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n2/2024 Removed Olumiant as a preferred product for RA. Updated state\nmandate footnote to 30-day trial for Connecticut.\n10/2024 Updated RA step requirement noting Adalimumab-adaz (unbranded\n© 2025 UnitedHealthcare Services, Inc.\n7\nHyrimoz), Amjevita for Nuvaila, and Humira as preferred adalimumab\nproducts with no change to clinical intent. Removed preferred\nadalimumab footnote.\n12/2024 Added Tyenne to coverage criteria with Actemra. Added T/F footnote.\nUpdated background and references.\n4/2025 Removed examples for adalimumab step therapy. Added the footnote\n“For a list of preferred products please reference drug coverage tools.”\n© 2025 UnitedHealthcare Services, Inc.\n8"
  ]
}